For decades, tiny membrane bubbles shed by bacteria were little more than a footnote in microbiology. First observed as obscure “small blobs” in electron micrographs, these structures – now known as outer membrane vesicles (OMVs) – were largely dismissed as cellular debris [1,2]. Today, that view has fundamentally changed. OMVs are emerging as powerful tools in vaccines, cancer immunotherapy, and drug delivery, reshaping how we think about bacteria and their biotechnological potential [2-5].
So how did we move from overlooked blobs to medically relevant nanoparticles?
The early discovery of outer membrane vesicles
The story of OMVs begins in the 1960s, when electron microscopy first revealed small spherical blebs budding from the outer membrane of Gram‑negative bacteria such as Escherichia coli and Neisseria species [1,3]. At the time, microbiology was shaped by the view of bacterial envelopes as tightly regulated and static. Material detaching from the surface was therefore interpreted as damage and these vesicles were largely dismissed as preparation artifacts, fragments from dying cells, or waste products of bacterial metabolism [2,3].
For nearly two decades, OMVs remained in scientific obscurity.
A shift in perspective: OMVs gain biological meaning
In the 1980s and 1990s, this perspective began to shift. Advances in imaging and biochemical analysis revealed that OMVs were not random fragments, but structured entities containing a consistent set of components – outer membrane proteins, lipopolysaccharide (LPS), and periplasmic enzymes – closely reflecting the architecture of the bacterial outer membrane [2,3]. Importantly, OMVs were shown to be released during normal bacterial growth, not only under stress or lysis [2]. Studies of pathogens such as Vibrio cholerae, Helicobacter pylori, and Neisseria meningitidis demonstrated that OMVs could transport toxins and virulence factors capable of directly interacting with host cells [2,6].
OMVs were no longer considered accidental debris, but intentional biological meaningful structures.
OMVs as a bacterial communication system
By the early 2000s, OMVs were widely recognized as a regulated secretion mechanism used by most Gram‑negative bacteria [2,3]. Far from being passive byproducts, they play active roles in delivering enzymes and toxins, transferring DNA and resistance genes, shaping biofilms, acting as decoys for antibiotics and bacteriophages, and modulating host immune responses [2,6,7]. Crucially, OMV cargo was shown to be selectively packaged, indicating that bacteria exert control over vesicle composition [2,7].
OMVs came to be understood as purpose‑built nanostructures refined by evolution.
From microbiology to medicine: The first vaccines
Notably, OMVs entered medical use before their biology was fully understood. In the 1990s, detergent-extracted OMVs derived from Neisseria meningitidis serogroup B were used to control meningitis outbreaks in Norway, Cuba, and New Zealand [4,5]. These vaccines demonstrated that OMVs could safely trigger strong immune responses, functioning as both antigen carriers and natural adjuvants [4]. While early formulations were strain‑specific, they paved the way for modern OMV‑based vaccines such as Bexsero®, which entered routine clinical use in the mid‑2010s [4,5].
This marked a turning point, establishing OMVs as viable pharmaceutical products.
Engineering the vesicle: When biology meets design
The 2010s marked a second major transformation, driven by advances in synthetic biology. Researchers developed methods to genetically modify bacteria to increase OMV production (hypervesiculating strains), reduce LPS‑associated toxicity, and display heterologous antigens on the vesicle surface [5,6]. Technologies such as GMMA (Generalized Modules for Membrane Antigens) enabled more scalable and controlled OMV manufacturing [5].
OMVs were no longer confined to their bacterial origins – they became programmable biological nanoparticles.
OMVs today: Beyond infectious disease
Today, OMVs extend well beyond infectious diseases applications. In addition to vaccine development targeting Neisseria gonorrhoea, Shigella, Salmonella, Haemophilus influenzae and SARS-CoV-2, their potential continues to expand.
Cancer immunotherapy: OMVs naturally activate the immune system through pathogen‑associated molecular patterns, making them attractive as cancer vaccines and immune stimulators, either alone or combined with tumor antigens [6-8].
Drug and nucleic acid delivery: With their natural membrane composition and efficient cellular uptake, OMVs are being explored as alternatives to synthetic lipid nanoparticles for delivering drugs, RNA, and DNA [6-8].
We can also see that diagnostics and microbiome research: Reflecting the molecular fingerprint of their parent bacteria, OMVs are also being investigated as biomarkers and tools to study host–microbe interactions [3,7].
Several engineered OMV platforms have now advanced into early‑phase clinical trials, signaling their transition into the translational space.
From Blobs to Breakthroughs
As we look back on the history of outer membrane vesicles it’s a reminder that biology often hides its most powerful ideas in plain sight. What once looked like meaningless membrane debris has become one of the most versatile platforms in modern biotech. OMVs are no longer just remnants of bacterial life – they are engineerable, scalable, and clinically relevant tools that shape the future of vaccines and therapeutics.
OMVs in practice: From concept to manufacturing reality
While interest in OMVs continues to accelerate, translating this biology into reproducible and scalable products remains a major challenge. Successful OMV‑based therapies require careful control of bacterial strains, vesicle composition, potency, and safety profiles, as well as robust analytical and manufacturing strategies.
With long‑standing experience in microbial process development and GMP manufacturing, we have worked closely with OMV‑based programs across early development and scale‑up. This hands‑on experience has highlighted both the promise and the complexity of OMVs, from strain engineering and vesicle yield optimization to downstream purification and quality control.
As OMVs move further into the clinical and commercial space, this combination of deep biological understanding and practical manufacturing expertise will be key to turning bacterial vesicles into reliable, patient‑ready medicines.
References
- Wang, J. et al. Outer membrane vesicles as a smart platform for biomedical applications. Cell Communication and Signaling 24, 124 (2026).
- Knox, K. W., et al. Electron microscopy of Gram‑negative bacterial membranes. J. Bacteriol. (1966).
- Schwechheimer, C. & Kuehn, M. J. Outer‑membrane vesicles from Gram‑negative bacteria. Nat. Rev. Microbiol. 13, 605–619 (2015).
- Zavan, L., Bitto, N. J., & Kaparakis‑Liaskos, M. Introduction, history, and discovery of bacterial membrane vesicles. In Bacterial Membrane Vesicles. Springer (2020).
- Lieberman, L. A. Outer membrane vesicles: a bacterial‑derived vaccination system. Front. Microbiol. 13, 1029146 (2022).
- Micoli, F., Adamo, R., & Nakakana, U. Outer membrane vesicle vaccine platforms. BioDrugs 38, 47–59 (2024).
- Zhao, X. et al. Bacterial outer membrane vesicles: structure, biogenesis and applications. Microbial Cell Factories 24, 27 (2025).
- Zhou, J. et al. Bacterial outer membrane vesicles: from physics to clinical. MedComm – Biomaterials and Applications (2025).